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Abstract
The	 phospholipid	 l-	α-	lysophosphatidylinositol	 (LPI),	 an	 endogenous	 ligand	 for	
GPR55,	 is	 elevated	 in	 patients	 with	 acute	 coronary	 syndrome,	 and	 a	 GPR55	 an-
tagonist	 cannabidiol	 (CBD)	 reduces	experimental	 ischemia/reperfusion	 (I/R)	 injury.	
While	LPI	activates	multiple	signaling	pathways,	little	is	known	about	which	ones	are	
important	 in	cardiomyocytes.	 In	 this	 study	we	explored	whether	activation	of	 the	
Rho	kinase/ROCK/p38	MAPK	pathway	is	responsible	for	LPI-	induced	extension	of	
I/R	injury.	Using	a	high-	throughput	screening	method	(dynamic	mass	redistribution;	
DMR),	mouse-	and	human-	induced	pluripotent	stem	cell	(iPSC)	cardiomyocytes	ex-
posed	to	LPI	were	shown	to	exhibit	a	rapid,	sustained,	and	concentration-	dependent	
(1	nmol	L−1-	30	μmol	L−1)	cellular	response.	Y-	27632	(ROCK	inhibitor;	10	&	50	μmol 
L−1)	and	CBD	(1	μmol	L−1)	both	abolished	the	DMR	response	to	LPI	(10	μmol	L−1).	In	
murine	 iPSC	cardiomyocytes,	LPI-	induced	ROCK	and	p38	MAPK	phosphorylation,	
both	of	which	were	prevented	by	Y-	27632	and	CBD,	but	did	not	induce	JNK	activa-
tion	or	cleavage	of	caspase-	3.	In	hearts	isolated	from	wild	type	(WT)	mice	subjected	
to	30	minutes	global	I/R,	LPI	(10	μmol	L−1)	administered	via	the	coronary	circulation	
increased	infarct	size	when	applied	prior	to	ischemia	onset,	but	not	when	given	at	the	
time	of	reperfusion.	The	exacerbation	of	tissue	injury	by	LPI	was	not	seen	in	hearts	
from	GPR55−/−	mice	or	in	the	presence	of	Y-	27632,	confirming	that	injury	is	mediated	
via	the	GPR55/ROCK/p38	MAPK	pathway.	These	findings	suggest	that	raised	levels	
of	LPI	in	the	vicinity	of	a	developing	infarct	may	worsen	the	outcome	of	AMI.
K E Y W O R D S
cell	signaling,	GPR55,	ischemia/reperfusion	injury,	lysophosphatidylinositol,	rho	kinase
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1  | INTRODUC TION
Reperfusion of an occluded artery is vital to the salvage of the 
myocardium	 affected	 by	 ischemia,	 however	 the	 reintroduction	
of	blood	and	oxygen	paradoxically	causes	further	 injury	and	car-
diomyocyte	 death	 known	 as	 ischemia/reperfusion	 (I/R)	 injury.12 
Immediate “lethal” I/R injury occurs within the first few minutes 
of reperfusion with the critical early events being an increase in 
oxidative	stress,	 [Ca2+]i	overload,
13 opening of the mitochondrial 
permeability	 transition	pore	 (MPTP15)	and	 the	activation	of	pro-	
apoptotic pathways.14,26 It is well established that the release of 
bioactive lipids from platelets at the site of clot formation during 
acute	 myocardial	 infarction	 (AMI)	 contributes	 to	 the	 eventual	
extent	of	myocardial	I/R	injury,	with	some	lipids	(eg	sphingosine-	
1-	phosphate;	 S-	1-	P)	 exerting	 cardioprotective	 effects	 (reviewed	
in	 21)	 and	 others	 exacerbating	 (eg	 platelet	 activating	 factor:	
22,32)	 I/R	 injury.	Platelets	also	 release	 the	 lysophospholipid	 l-	α-	
lysophosphatidylinositol	 (LPI)	 and	 are	 thought	 to	 be	 the	 source	
of	 the	elevated	plasma	 levels	of	LPI	 seen	 in	patients	undergoing	
coronary	 angioplasty	 for	 acute	 coronary	 syndrome	 (ACS27).	 LPI	
acts	 as	 an	endogenous	 ligand	at	 the	G-	protein	 coupled	 receptor	
GPR5536	which	is	expressed	in	various	rodent40 and human18 tis-
sues	including	the	cardiovascular	system,	where	it	is	expressed	on	
vascular smooth muscle and endothelial cells6,7 and ventricular 
cardiomyocytes.45,52
Although	the	functional	importance	of	the	GPR55/LPI	system	
in cardiovascular physiology and pathophysiology is poorly under-
stood,	we	have	previously	shown	that	mice	lacking	GPR55	exhibit	
moderate systolic dysfunction with age and have a decreased 
contractile	 reserve	 in	 response	 to	 adrenoceptor	 stimulation,45 
suggesting a physiological role in maintaining cardiac function. In 
contrast,	observations	that	GPR55	tissue	expression	and	circulat-
ing	levels	of	LPI	are	raised	in	conditions	where	there	is	heightened	
cardiovascular	 risk	 (such	 as	 obesity	 and	metabolic	 syndrome33);	
that	 cardiac	 LPI	 levels	 rise	 during	 asphyxia-	induced	 myocardial	
ischemia,24,25	and	that	 the	GPR55	antagonist	CBD	reduces	myo-
cardial infarct size in rats in vivo9,46 all point to a potential detri-
mental	 role	 for	LPI/GPR55	 in	cardiovascular	pathologies	 such	as	
AMI.
Studies	 in	 GPR55-	expressing	 HEK	 cells	 have	 linked	 GPR55-	
mediated	 LPI	 responses	 to	 activation	 of	 several	 signaling	 path-
ways,	 including	 activation	 of	 RhoA	 and	 ROCK	 resulting	 in	 an	
increase	 in	 intracellular	calcium	 ([Ca2+]i)	 and	activation	of	Gα13.
17 
Similarly,	 LPI	 induces	 a	 rapid	 and	 transient	 increase	 in	 [Ca2+]i in 
cardiomyocytes	 through	 an	 action	 at	 GPR55	 receptors	 located	
on both the sarcolemma and the membranes of intracellular or-
ganelles,52	although	any	involvement	of	RhoA/ROCK	signaling	in	
the	response	to	LPI	in	cardiomyocytes	remains	to	be	investigated.	
[Ca2+]i overload is a major factor in cardiomyocyte death follow-
ing myocardial I/R5,28	and	activation	of	the	RhoA/ROCK	pathway	
plays an important role in the setting of I/R injury as it is acti-
vated	at	the	time	of	reperfusion	to	suppress	the	RISK	pathway	and	
extend	reperfusion	injury.14	Thus,	our	underlying	hypothesis	was	
that	activation	of	the	GPR55/RhoA/ROCK	pathway	by	LPI	in	the	
vicinity	of	the	ischemic	myocardium,	may	contribute	to	exacerba-
tion	of	I/R	injury.	To	explore	this,	we	initially	confirmed	in	murine	
and	human	iPSC	cardiomyocytes	that	activation	in	response	to	LPI	
is	mediated	by	GPR55,	utilizing	a	well-	established	label-	free,	high-	
throughput	screening	system	(Corning®	Epic®)	that	measures	the	
dynamic	mass	redistribution	(DMR)	of	cells	and	enables	real-	time	
detection of integrated cellular responses in living cells.41 This al-
lowed us to make a rapid determination of the optimum concen-
tration	and	exposure	time	to	LPI	for	subsequent	studies	in	murine	
iPSC	 cardiomyocytes	 and	 isolated	 Langendorff-	perfused	 hearts,	
which	were	undertaken	to	confirm	that	stimulation	of	GPR55	by	
LPI	 leads	 to	 activation	 of	 the	 RhoA/ROCK/p38	MAPK	 pathway	
and	to	an	exacerbation	of	myocardial	injury	in	cultured	cardiomy-
ocytes	and	isolated	hearts,	respectively.
2  | MATERIAL S AND METHODS
2.1 | Dynamic mass redistribution (DMR) in 
response to LPI
The	underlying	principle	of	determining	changes	in	cellular	DMR	has	
previously been described in detail.10,11,41	To	measure	DMR,	cells	are	
seeded on to a microplate containing a resonant waveguide grating 
biosensor,	which	measures	changes	in	the	local	 index	of	refraction	
upon mass redistribution within a living cell monolayer grown on the 
biosensor.	When	a	receptor	is	stimulated	by	a	ligand,	the	change	in	
DMR	in	the	cells	is	manifested	as	a	shift	in	the	wavelength	of	light	
that is reflected from the sensor. The magnitude of this wavelength 
shift	is	proportional	to	the	total	change	in	the	biomass	proximal	to	
the	 sensor	 surface	 (amount	 of	DMR)	 and	 thus	GPCR	 activation	 is	
translated	 into	 signaling	 pathway-	specific	 optical	 signatures.	 This	
technique	 has	 been	 previously	 used	 to	 demonstrate	 activation	 of	
GPR55	 in	 other	 cell	 types,19	 but	 not	 in	 cardiomyocytes,	 and	 has	
been	 identified	 as	 the	 preferred	 assay	 technique	 to	 study	GPR55	
pharmacology and function since it provides a much more accu-
rate	 determination	 of	 agonist	 potency.	 In	 the	 present	 studies,	 to	
measure	the	DMR	in	response	to	LPI,	murine	(Cor.At®	CL-	i;	source	
tissue	mouse	 tail	 tip;	miPSC)	 and	 human(iCell®;	 1099441;	 hiPSC)-	
induced	 pluripotent	 stem	 cell	 (iPSC)	 cardiomyocytes	were	 seeded	
(miPSCs—7500	per	well;	hiPSCs—12,000	per	well)	in	Epic® 384 Well 
fibronectin	coated	cell	assay	microplates	using	a	Multi-	drop	Combi	
cell	 dispenser	 (Thermo	 Electron	 Corporation,	 UK)	 and	 cultured	
(37°C	in	5%	CO2)	in	Cor.At
®	medium	for	7	days	(miPSC	cardiomyo-
cytes)	or	12	hours	(hiPSC	cardiomyocytes)	until	80%-	100%	conflu-
ent.	Post	culture,	each	well	was	gently	washed	with	buffer	(Hank's	
Balanced	Salt	Solution;	HBSS,	20	mmol	L−1	4-	(2-	hydroxyethyl)-	1-	pip
erazineethanesulfonic	acid	 (HEPES),	0.01%	Bovine	Serum	Albumin	
(BSA;	essentially	fatty	acid	free,	≥96%)	and	0.0005%	dimethyl	sul-
foxide	(DMSO);	pH7.4)	using	an	ELxMicroplate	Washer	(Bio-	Tek)	and	
the	microplates	incubated	at	26°C	for	1	hour.	Baseline	readings	were	
then	taken	every	minute	for	a	3-	minute	period	prior	to	addition	of	
LPI	alone	(1	nmol	L−1-	30	μmol	L−1),	or	LPI	(10	μmol	L−1)	in	the	presence	
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of	the	GPR55	antagonist	cannabidiol	(CBD;	1	μmol	L−1),	or	the	ROCK	
inhibitor	Y-	27632	(10	and	50	μmol	L−1),	using	a	Biomek®NMP labora-
tory	automated	workstation	(Beckman	Coulter,	Sweden);	100	μmol 
L−1	ATP	was	used	as	a	positive	control.	The	microplate	was	then	rein-
serted into the Corning®Epic®	System	and	the	DMR	measurements	
in	each	well	were	recorded	at	1-	minute	intervals	over	a	90-	minute	
time	period.	To	confirm	that	any	effects	of	Y-	27632	and	CBD	on	LPI	
responses	were	not	due	to	a	cytotoxic	effect,	cell	viability	of	miPSC	
cardiomyocytes	 exposed	 to	 CBD	 (1	 μmol	 L−1)	 or	 Y-	27632	 (10	 and	
50	μmol	L−1)	for	90	minutes	was	determined	using	an	MTT	(3-	(4,5-	d
imethylthiazol-	2-	yl)-	2,5-	diphenyltetrazolium	bromide)	assay.	Briefly,	
miPSC	 cardiomyocytes	were	 seeded	 at	 a	 density	 of	 20,000	 cells/
well	 in	a	96-	well	plate	and	cultured	 in	Cor.At®	media	 (supplied	by	
the	manufacturer)	for	7	days	at	37°C	(in	5%	CO2).	Following	treat-
ment	 with	 pharmacological	 agents,	 media	 was	 removed,	 replaced	
with	MTT	(1	mg/mL)	and	plates	incubated	for	4	hour	at	37°C.	The	
formazan	product	was	then	dissolved	by	adding	DMSO	to	the	wells	
and	absorbance	measured	at	560	nm	using	a	plate	reader	(Bio-	Tek).
2.2 | Activation of downstream signaling pathways 
by LPI in miPSC cardiomyocytes
Activation	of	ROCK,	p38	MAPK,	 JNK,	 and	caspase-	3	 cleavage	 in	
response	to	LPI	stimulation	was	determined	in	miPSC	cardiomyo-
cytes	cultured	as	described	in	Section	2.1.	Experiments	were	per-
formed	 with	 cells	 grown	 at	 a	 confluency	 of	 70%-	80%	 and	 then	
serum	 starved	 overnight	 (16	 hours)	 prior	 to	 experimentation.	
Following	challenge	with	LPI,	with	or	without	the	ROCK	inhibitor	
Y-	27632	or	 the	GPR55	antagonist	CBD,	 the	 cells	were	 lysed	 and	
the	resulting	 lysates	subjected	to	SDS-	PAGE	and	 immunoblotting	
as previously described.19	Briefly,	following	cell	treatment,	the	cells	
were	washed	with	ice-	cold	PBS	and	then	immediately	lysed	in	ice	
cold	lysis	buffer	(50	mmol	L−1	Tris/HCl	pH	7.4,	0.27	mol	L−1	sucrose,	
1	mmol	 L−1	 sodium	orthovanadate,	1	mmol	 L−1	EDTA,	1	mmol	 L−1 
EGTA,	 10	mmol	 L−1	 sodium	2-	glycerophosphate,	 50	mmol	 L−1 so-
dium	 fluoride,	5	mmol	L−1	 sodium	pyrophosphate,	1%	 (v/v)	Triton	
X-	100,	 0.1%	 (v/v)	 2-	mercaptoethanol	 and	 protease	 inhibitor	 (one	
tablet/50	 mL)).	 Cell	 debris	 was	 removed	 from	 crude	 cell	 lysates	
by centrifugation at 3000g	 for	10	minutes	at	4°C,	and	the	result-
ing	 supernatant	 used	 for	 Western	 blot	 analysis.	 Proteins	 from	
cell	 lysates	 (30	μg)	were	 fractionated	 by	 SDS-	polyacrylamide	 gel	
electrophoresis	and	immunoblotted	using	anti-	phospho	(Ser1366)	
ROCK2	 (Genetex,	 Irvin,	 CA,	USA),	 anti-	Actin	 (MilliporeSigma,	 St.	
Louis,	MO,	USA),	 anti-	phospho	 (Thr180/Tyr182)	p38	MAPK	 (Cell	
Signaling	Technology,	Danvers,	MA,	USA),	anti-	phospho	(Thr183/
Tyr185)	JNK	(Cell	Signaling	Technology,	Danvers,	MA,	USA),	cleaved	
caspase-	3	(Asp	175)	and	native	ROCK2	(Cell	Signaling	Technology,	
Danvers,	 MA,	 USA)	 antibodies.	 Primary	 antibody	 detection	 was	
carried	out	using	a	horseradish	peroxidase-	conjugated	anti-	rabbit	
IgG	antibody	(New	England	Biolabs,	Hitchin,	Herts,	UK)	and	visu-
alized by enhanced chemiluminescence. Resulting band intensi-
ties	were	quantified	using	ImageJ	software	(National	Institutes	of	
Health,	Bethesda,	MD).
2.3 | Isolated heart studies
All	 studies	 were	 performed	 under	 a	 Project	 License	 authorized	
under	 the	 UK	 Animals	 (Scientific	 Procedures)	 Act	 1986,	 conform	
to	 the	 guidelines	 from	 Directive	 2010/63/EU	 of	 the	 European	
Parliament	on	the	protection	of	animals	used	for	scientific	purposes	
and	are	reported	in	line	with	the	ARRIVE	guidelines.23	Male	and	fe-
male	wild	 type	 (WT)	mice	 (C57BL/6J;	 JAX	background)	were	pur-
chased	from	Charles	River	Laboratories	International	Inc.	(Margate,	
UK),	 while	 homozygous	 GPR55	 knockout	 (GPR55−/−;	 JAX	 back-
ground)	mice	were	bred	in-	house	and	were	routinely	genotyped	as	
previously described.49	 All	 animals	were	 housed	 in	 the	University	
of	 Aberdeen	 Medical	 Research	 Facility	 until	 experimentation	 at	
Robert	 Gordon	 University.	 All	 mice	 were	 grouped	 according	 to	
genotype,	 gender	 and	 age	 and	 housed	 in	 temperature	 (21	 ±	 2°C)	
and	 humidity	 (55	 ±	 10%)	 controlled	 rooms	 with	 a	 12-	hour	 light/
dark	cycle	 (7	am/7	pm).	Additionally,	mice	were	housed	(according	
to	husbandry	guidelines	set	by	the	UK	Home	Office)	in	groups	not	
exceeding	 eight,	with	 ad	 libitum	 access	 to	water	 and	 food	 pellets	
and	environmental	enrichment.	All	animals	(males	and	females)	were	
aged	between	9-	12	weeks	(body	weights	18-	32	g)	at	the	time	of	use	
and	were	randomly	allocated	to	experimental	groups	using	random	
number	generator	software	(Stat	Trek,	UK).
Mice	were	anesthetized	with	ketamine	(120	mg/kg)	and	xyla-
zine	(16	mg/kg)	via	intraperitoneal	(ip)	injection	and	the	heart	rap-
idly	excised,	the	aorta	cannulated	and	the	heart	mounted	onto	a	
Langendorff	retrograde	perfusion	apparatus	(AD	Instruments	Ltd,	
UK)	and	perfused	with	Kreb's	Henseleit	buffer	(119	mmol	L−1	NaCl,	
4.7	mmol	L−1	KCl,	1.18	mmol	L−1	KH2PO4,	2.41	mmol	L
−1	MgSO4,	
25	mmol	 L−1	NaHCO3,	 2.52	mmol	 L
−1 CaCl2	 and	 10.88	mmol	 L
−1 
C6H12O6;	 pH	 7.4;	 37°C;	 2-	2.5	 mL/min).	 Following	 a	 15-	minute	
stabilization	 period,	 since	 flow	 to	 the	 heart	 was	 to	 be	 stopped	
during	global	 ischemia,	a	slow	bolus	 injection	of	LPI	 (500	μL	of	a	
10 μmol	L−1	solution	over	a	30	second	period)	or	vehicle	 (500	μL	
of	0.1%	DMSO)	was	administered	via	a	side-	port	of	the	aortic	can-
nula	 10	minutes	 prior	 to	 30	minutes	 of	 no-	flow	 global	 ischemia	
followed	by	30	minutes	reperfusion.	This	concentration	of	LPI	was	
used	 to	 reflect	 the	LPI	 levels	present	 in	 the	coronary	circulation	
seen	in	clinical	cases	of	acute	coronary	syndrome	(1-	12	μmol	L−1),	
and	the	DMR	and	ROCK	phosphorylation	studies	had	confirmed	
that	the	peak	response	to	LPI	develops	within	10	minutes	and	 is	
sustained	for	>40	minutes.	At	the	end	of	each	protocol,	the	hearts	
were	frozen	(−20°C	for	24	hours),	sliced	into	four	sections	(2-	3	mm	
thickness)	 and	 the	 third	 section	 from	 the	 apex	 stained	 with	
2,3,5-	Triphenyl-	tetrazolium	chloride	 (TTC;	1%)	 for	30	minutes	at	
37°C	 to	 distinguish	 between	 viable	 and	 necrotic	 tissue,	 fixed	 in	
10%	neutral	buffered	formalin	(Formal	Fixx™)	for	2	hours	and	then	
photographed	with	an	EOS	1100D	camera	(Canon,	UK)	attached	
to	a	Leica	S4E	microscope	 (Leica	Microsystems	Ltd,	UK).	 Images	
were	subsequently	coded	for	blinded	analysis	and	infarct	size	de-
termined	 via	 computerized	 planimetry	 (ImageJ	 software)	 where	
red and white staining was indicative of healthy and infarcted tis-
sue,	respectively.
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2.4 | Statistical analysis
For	all	experiments,	data	are	expressed	as	mean	±	SEM	of	n	observa-
tions.	For	the	ROCK2	phosphorylation	assay,	n	refers	to	the	number	
of	experiments	performed	using	separate	cell	preparations	and	data	
were	expressed	as	 a	 ratio	of	phospho-	ROCK2	 to	ROCK2.	For	 the	
Epic	 studies,	 the	 time	 courses	of	 the	 responses	were	obtained	by	
plotting	the	DMR	activity	(arbitrary	units)	measured	at	1-	minute	in-
tervals	and	peak	DMR	activity	was	determined	from	the	time	course	
plots	and	measured	at	the	point	where	the	response	reached	a	maxi-
mum before either reaching a plateau or declining; n refers to the 
number	 of	 plates	 tested	 for	 each	 intervention.	 For	 isolated	 heart	
studies,	 n	 refers	 to	 the	 number	 of	 hearts	 or	 tissue	 samples	 used	
for	the	study.	Power	calculations	performed	on	data	from	previous	
studies	indicated	that	to	detect	a	30%	difference	in	infarct	size	with	
85%	power,	the	minimum	group	size	is	5.	Therefore,	all	experiments	
employed hearts from at least five animals for each intervention. 
However,	 since	 the	 studies	were	 performed	 over	 several	months,	
contemporaneous	 control	 experiments	 in	wild	 type	mice	were	 in-
cluded throughout to avoid any influence of seasonal variation 
and	therefore	the	data	were	pooled,	resulting	in	larger	group	sizes.	
Infarct	 size	 is	 expressed	 as	 a	 percentage	 of	 total	 ventricular	 area	
of	the	tissue	slice.	For	both	cell	studies	and	isolated	heart	studies,	
comparisons	were	made	using	either	Student's	unpaired	t-	test	(two-	
group	 comparison)	 or	 one-	way	 ANOVA	 followed	 by	 a	 Bonferroni	
post-hoc	 test	 (multiple	 comparisons).	 All	 statistical	 analyses	 were	
carried	out	using	GraphPad	Prism®4	software	(GraphPad	Software,	
Inc.	USA).	In	all	cases	a	value	of	P	<	0.05	was	taken	to	indicate	sta-
tistical significance.
2.5 | Drugs and solutions
LPI	 sodium	 salt	 from	 Glycine max	 (soybean),	 CID-	16020046,	 TTC,	
PBS,	BSA,	Cor.At®	CL-	i	cardiomyocytes	(miPSC	cardiomyocytes)	1M	
kit	with	puromycin	and	Cor.At®	medium,	HBSS	and	all	 the	compo-
nents	for	Kreb's	Henseleit	solution	(with	the	exception	of	NaCl	and	
NaHCO3)	 were	 all	 purchased	 from	 Sigma	 Aldrich
®,	 UK.	 Ketamine	
(Vetalar™)	 and	 Xylazine	 (Rompun®)	 were	 obtained	 from	 Pfizer	 and	
Bayer	Healthcare	 (both	Dublin,	 Ireland)	 respectively.	Y-	27632	dihy-
drochloride	was	purchased	 from	Tocris	Bioscience	 (Abingdon,	UK).	
NaCl,	NaHCO3,	and	DMSO	were	bought	from	Fisher	Scientific,	UK.	
Formal	Fixx™	was	supplied	by	Thermo	Fisher	Scientific,	UK.	HEPES	
was	 bought	 from	 Invitrogen,	 UK.	 Corning®	 Epic®	 384	 Well	 Cell-	
Based	Assay	Microplates	were	acquired	from	Corning	Life	Sciences,	
UK.	 Human	 iPSC	 Cardiomyocytes	 (hiPSC	 cardiomyocytes;	 iCell® 
Cardiomyocytes)	were	acquired	from	Cellular	Dynamics®,	US.
3  | RESULTS
3.1 | Effect of LPI on cultured cardiomyocytes—
identification of ROCK as a GPR55 signaling pathway
In	order	to	explore	whether	LPI,	acting	through	GPR55	and	ROCK,	
could	have	an	adverse	effect	on	the	outcome	of	AMI,	it	was	impor-
tant	to	initially	characterize	the	responses	to	LPI	in	cardiomyocytes.	
Concentration-	response	 studies	 in	 murine	 iPSC	 cardiomyocytes	
demonstrated	 that	 LPI-	induced	 DMR	 activity	 in	 a	 concentration-	
dependent	 manner	 (1	 nmol	 L−1-	30	 μmol	 L−1;	 EC50	 778	 nmol	 L
−1; 
Figure	1A)	and	that	the	time	course	of	the	DMR	response	was	rapid	
F IGURE  1 LPI	induces	a	rapid,	concentration-	dependent	increase	in	dynamic	redistribution	(DMR)	in	murine	iPSC	cardiomyocytes.	LPI	
(1	nmol	L−1-	30	μmol	L−1)	induced	a	concentration-	dependent	increase	in	peak	DMR	activity	(Panel	A)	that	reached	a	peak	within	10	minutes	
and	was	sustained	for	the	90-	minute	measurement	period	(Panel	B).	ATP	(100	μmol	L−1)	was	employed	as	a	positive	control	in	all	experiments	
(Panel	C).	The	maximum	response	seen	with	10	μmol	L−1	LPI	was	significantly	greater	than	the	response	to	the	vehicle	(0.1%	DMSO;	Panel	
C; *P	<	0.05	vs	vehicle).	Values	are	shown	as	mean	±	SEM	(Panels	A	&	D)	or	as	averaged	values	(Panels	B	&	C);	n	=	3	experiments	performed	
using	different	cell	preparations.	AU	=	Arbitrary	Units
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in	onset,	 reached	peak	activity	at	10	minutes	post	application	and	
persisted	 for	 the	duration	of	 the	period	of	measurement	 (90	min-
utes;	Figure	1B).	Since	data	from	clinical	cases	of	acute	coronary	syn-
drome	have	found	plasma	LPI	levels	to	be	in	the	region	of	1-	12	μmol 
L−1,27 we chose to use 10 μmol	L−1	LPI	for	subsequent	experiments	
since this is in the upper range of clinical data and produced a re-
sponse	of	 sufficient	magnitude	 and	duration	 (Figure	1C	 and	D)	 to	
be sustained throughout the I/R protocol used in the isolated heart 
studies	(70	minutes	in	total).
Both	the	peak	(Figure	2A)	and	time-	dependent	(Figure	2B)	DMR	
response	 to	 LPI	 in	 murine	 iPSC	 cardiomyocytes	 were	 completely	
prevented	by	CBD	across	the	full	concentration	range	of	LPI,	while	
CBD	alone	did	not	induce	a	cellular	response,	confirming	an	action	
of	LPI	through	activation	of	GPR55.	The	ROCK	inhibitor	Y-	27632	(10	
and	50	μmol	L−1)	similarly	completely	prevented	the	LPI-	induced	in-
crease	in	DMR	activity	at	all	concentrations	of	LPI	(data	for	10	μmol 
L−1	 shown	 in	 (Figure	 2C	 and	 D),	 demonstrating	 that	 LPI	 activates	
ROCK	 downstream	 of	 GPR55	 in	 murine	 iPSC	 cardiomyocytes.	
Neither	CBD	(10	μmol	L−1)	nor	Y-	27632	(10	μmol	L−1	and	50	μmol	L−1)	
had	any	effect	on	cell	 viability	 (Figure	2E).	Finally,	 to	confirm	 that	
findings	from	a	murine	stem	cell-	derived	cardiomyocyte	line	can	be	
translated	to	humans,	the	experiments	performed	in	the	murine	cells	
were	repeated	with	human	iPSC	cardiomyocytes	and	demonstrated	
that	LPI	exhibits	exactly	the	same	pattern	of	activity	over	the	same	
concentration	range	(EC50	282	nmol	L
−1;	Figure	3A	and	B)	and	was	
similarly	GPR55	and	ROCK-	mediated	as	shown	by	inhibition	by	CBD	
(Figure	3C)	and	Y-	27632	(Figure	3D),	respectively.
3.2 | LPI induces ROCK and p38 MAPK 
phosphorylation in murine iPSC cardiomyocytes
To	confirm	that	the	changes	in	DMR	in	response	to	LPI	were	indeed	
associated	 with	 ROCK	 and	 p38	 MAPK	 phosphorylation,	 murine	
iPSC	cardiomyocytes	were	stimulated	with	LPI	alone	(1	&	10	μmol 
L−1	for	10	minutes),	or	with	LPI	(10	μmol	L−1)	in	the	absence	or	pres-
ence	of	CBD	(1	μmol	L−1)	or	Y-	27632	(50	μmol	L−1)	prior	to	Western	
blotting.	As	with	the	DMR	studies,	LPI-	induced	an	increase	in	both	
ROCK	(1	and	10	μmol	L−1	LPI;	Figure	4A)	and	p38	MAPK	(10	μmol	L−1 
LPI;	Figure	4C)	phosphorylation	that	was	completely	abrogated	by	
both	CBD	(1	μmol	L−1)	and	Y-	27632	(50	μmol	L−1;	Figure	4B	and	C).	In	
contrast,	challenging	cells	with	10	μmol	L−1	LPI	did	not	result	in	any	
significant	 alterations	 in	 either	 JNK	 phosphorylation	 or	 caspase-	3	
activation	(Figure	4	D	and	E).
To	demonstrate	that	ROCK	activation	persists	for	the	duration	
of global ischemia during the I/R protocol to be used in the subse-
quent	 isolated	 perfused	 heart	 experiments,	 ROCK	 activation	 was	
determined	 in	murine	 iPSC	 cardiomyocytes	 following	 exposure	 to	
LPI	(10	μmol	L−1)	for	either	10	or	40	minutes.	Additionally,	since	CBD	
has	complex	pharmacological	activity	beyond	GPR55	antagonism	(eg	
antagonism	at	CB1
47;	and	inverse	agonism	at	CB2	receptors,
37),	the	
role	of	GPR55	 in	mediating	 the	 responses	 to	LPI	was	 further	con-
firmed	in	these	experiments	by	using	the	selective	GPR55	antago-
nist	CID16020046	(10	μmol	L−1).	ROCK	phosphorylation	by	LPI	was	
still	 clearly	 detectable	 after	 40	minutes	 (Figure	5A	 and	B)	 and,	 as	
with	CBD,	CID16020046	completely	abrogated	 the	 response	pro-
viding	further	confirmation	that	this	was	mediated	through	GPR55	
activation.
3.3 | LPI exacerbates I/R injury via activation of 
GPR55 and ROCK phosphorylation
To	 confirm	 that	 LPI	was	 acting	 through	GPR55,	 hearts	 from	both	
WT	and	GPR55−/−	mice	were	used.	Challenging	WT	hearts	with	LPI	
prior to the onset of global ischemia significantly increased infarct 
size	compared	to	vehicle	controls	(Figure	6A,	B	and	G),	whereas	this	
was	not	seen	in	seen	GPR55−/−	hearts,	confirming	an	action	of	LPI	
at	GPR55	(Figure	6E	and	F).	Interestingly,	when	LPI	was	applied	to	
the	 hearts	 within	 the	 first	 1-	2	 minutes	 of	 reperfusion,	 there	 was	
no	 increase	 in	 infarct	 size,	 indicating	 that	 the	 cellular	mechanisms	
that	contribute	to	LPI-	induced	injury	are	activated	during	ischemia	
(Figure	6G).	When	the	ROCK	inhibitor	Y-	27632	(10	and	50	μmol	L−1; 
volume	delivered	500	μL	over	30	second)	was	applied	to	WT	hearts	
via	the	aortic	cannula	5	minutes	prior	to	administration	of	either	LPI	
or	 vehicle,	 the	 LPI-	induced	 exacerbation	 of	 infarct	 size	was	 abro-
gated	by	the	higher	concentration	(Figure	6C,	D	and	H),	implicating	
ROCK	in	the	signaling	pathway	downstream	of	GPR55.	Interestingly,	
infarct	 size	 did	 not	 significantly	 differ	 between	 vehicle-	treated	
hearts	from	WT	and	GPR55−/−	mice.	This	 indicates	that,	at	 least	 in	
isolated	hearts,	 the	 induction	of	 ischemia	does	not	 induce	cardiac	
release	of	LPI.
4  | DISCUSSION AND CONCLUSIONS
The data presented from this study has shown for the first time that 
LPI,	 a	 platelet-	derived	 lysophospholipid	 that	 is	 elevated	 in	 acute	
coronary	syndrome,	exacerbates	the	extent	of	myocardial	injury	and	
that,	as	 in	other	cell	 types,	LPI	exerts	 its	cellular	 responses	 in	car-
diomyocytes	via	activation	of	the	GPR55	receptor	and	downstream	
activation	of	both	ROCK	and	p38	MAPK.
4.1 | LPI signaling in cardiomyocytes
Despite	 strong	 evidence	 that	 LPI-	induced	 RhoA/ROCK	 signaling	
is	 important	 in	 other	 cell	 types,	 this	 pathway	 has	 not	 previously	
been	 investigated	 in	 cardiomyocytes.	 Using	 a	 high-	throughput	
(Corning®Epic®)	technique41	to	measure	DMR,	which	has	previously	
been	 used	 to	 explore	 cellular	 responses	 to	GPR55	 ligands	 (includ-
ing	 LPI),19	 we	 have	 demonstrated	 the	 concentration	 dependency,	
time	course,	and	the	magnitude	of	the	LPI	response	 in	murine	and	
human-	induced	pluripotent	 stem	 cell-	derived	 cardiomyocytes.	 The	
characteristics	of	the	LPI	response	in	cardiomyocytes	are	similar	to	
those	reported	in	HEK293	cells,	and	our	demonstration	that	the	LPI	
response	is	susceptible	to	blockade	by	both	CBD	and	Y-	27632	is	con-
sistent with studies in both cancer3	and	HEK29317,19	cells.	Crucially,	
we	were	able	to	establish	identical	responses	to	LPI,	and	blockade	by	
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F IGURE  2 The	DMR	response	in	murine	iPSC	cardiomyocytes	is	inhibited	by	the	GPR55	antagonist	CBD	and	the	ROCK	inhibitor	
Y-	27632.	The	GPR55	antagonist	CBD	(1	μmol	L−1)	abrogated	the	peak	DMR	response	over	the	full	concentration	range	of	LPI	(1	nmol	L−1-	
30 μmol	L−1;	Panel	A)	tested.	Both	CBD	(1	μmol	L−1;	Panel	B)	and	Y-	27632	(10	&	50	μmol	L−1;	Panel	C)	suppressed	all	phases	of	the	DMR	
response	to	LPI	(10	μmol	L−1)	during	the	90-	minute	measurement	period	and	markedly	reduced	the	peak	DMR	response	to	LPI	(Panel	D).	
Neither	CBD	(1	μmol	L−1)	nor	Y-	27632	(10	&	50	μmol	L−1)	demonstrated	any	cytotoxic	effects	against	the	cardiomyocytes	as	determined	
by	MTT	assay	(Panel	E).	ATP	(100	μmol	L−1)	was	employed	as	a	positive	control	in	all	experiments	measuring	DMR.	Values	are	shown	as	
mean	±	SEM	(Panels	A,	D,	&	E)	or	as	averaged	values	(Panels	B	&	C);	n	=	3-	4	experiments	performed	using	separate	cell	preparations	for	all	
groups. #P < 0.001 vs vehicle; *P <	0.001	vs	LPI	alone.	AU=Arbitrary	Units
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CBD	and	Y-	27632,	 in	both	murine	 and	human-	induced	pluripotent	
stem	cell	cardiomyocytes,	establishing	that	the	same	signaling	path-
way	is	important	in	both	species.	In	HEK293	cells,	GPR55	activation	
leads	to	the	recruitment	of	several	nuclear	transcription	factors,	all	
of	which	activate	RhoA	leading	to	phosphorylation	of	ROCK.17,19 In 
these	present	studies,	we	have	shown	for	the	first	time	that	exposure	
of	miPSC	cardiomyocytes	to	LPI	induces	both	ROCK	and	p38	MAPK	
activation,	and	that	this	is	dependent	upon	an	action	at	GPR55.
In	cardiomyocytes,	one	consequence	of	p38	MAPK	activation	is	
the	induction	of	apoptosis,39 however we did not see any activation 
of	JNK	or	caspase-	3	(both	markers	of	apoptosis),	suggesting	that	the	
increased	injury	seen	in	the	isolated	hearts	challenged	with	LPI	prior	
to I/R was not due to induction of apoptotic cell death but to some 
other	mechanism,	such	as	calcium	overload.	It	has	been	previously	
shown	 that	 LPI	 directly	 increases	 cardiomyocyte	 [Ca2+]i through 
activation	of	both	sarcolemmal	GPR55	receptors,	to	stimulate	Ca2+ 
entry	via	L-	type	Ca2+channels	(LTCC)	and	IP3-	mediated	Ca
2+ release 
from	internal	stores,	and	intracellular	GPR55	receptors	that	promote	
internal Ca2+	release	via	endolysosomal	NAADP-	sensitive	two-	pore	
channels.52 There is generally scant information on any association 
between	ROCK	activation	and	increases	in	[Ca2+]i,	and	indeed	RhoA	
and Ca2+ signaling pathways have been traditionally regarded as 
being	distinct	from	each	other,	and	so	quite	how	LPI-	induced	ROCK	
activation	links	to	the	reported	LPI-	induced	increases	in	cardiomyo-
cyte [Ca2+]i	 remains	 elusive.	However,	 a	 link	 between	ROCK	 acti-
vation and increases in [Ca2+]i	has	been	seen	in	HEK	cells,	where	a	
RhoA-	dependent	 Ca2+	 signaling	 pathway	 mediates	 LPI-	induced	
NFAT	activation,17 suggesting that in some tissues these pathways 
converge.	 Indeed,	 LPI	 causes	 a	 biphasic	 increase	 in	 [Ca2+]i,	 in	 en-
dothelial	 cells,	 the	 first	 phase	 of	which	 is	 PLC-	IP3-	dependent	 and	
the	second	phase,	ROCK-	dependent.1	Therefore,	 it	 is	 feasible	 that	
ROCK	activation	in	cardiomyocytes	is	similarly	linked	to	changes	in	
intracellular calcium.
Although	this	study	has	focused	on	the	ROCK/p38	MAPK	path-
way,	LPI	has	been	shown	to	activate	additional	signaling	pathways	
on	noncardiomyocyte	cells,	including	JNK	and	AKT/ERK.	However,	
as	described	above,	we	did	not	see	any	notable	JNK	activation,	and	
we have found previously in rat neonatal cardiomyocytes that the 
activation	of	ERK	in	response	to	LPI	is	very	transient	(5	minutes)	and	
would therefore be unlikely to account for the sustained response to 
LPI	seen	in	the	DMR	studies	(Figure	S1;	unpublished	observations).
4.2 | Mechanisms of LPI- induced 
cardiomyocyte injury
Total	 levels	 of	 LPI	 in	 the	 coronary	 circulation	 during	AMI	 are	 sig-
nificantly	elevated	(mean	2.95	±	1.88	μmol	L−1;	range	1-	12	μmol	L−1),	
compared to levels seen in either stable angina or no coronary ar-
tery	disease	(mean	1.54	±	0.99	μmol	L−1;	range	1-	5	μmol	L−1	27)	and	
it	is	believed	that	the	LPI	is	released	from	platelets	activated	at	the	
site	of	plaque	rupture	and	clot	 formation,	 rather	 than	the	myocar-
dium per se.	Platelet-	derived	substances	released	during	AMI	have	
ready	 access	 (via	 the	 coronary	 circulation)	 to	 the	 cardiac	 tissue	 in	
the vicinity of their release and therefore could influence the in-
jury	 process	 within	 cardiac	 tissue.	 By	 using	 an	 isolated	 perfused	
heart	model,	we	have	demonstrated	that	application	of	LPI	via	the	
F IGURE  3 The	DMR	response	to	LPI	in	human	iPSC	cardiomyocytes	is	identical	to	that	seen	in	murine	iPSC	cardiomyocytes	and	is	
similarly	inhibited	by	the	GPR55	antagonist	CBD	and	the	ROCK	inhibitor	Y-	27632.	LPI	(1	nmol	L−1-	30	μmol	L−1)	produced	a	concentration-	
dependent	increase	in	peak	DMR	response	in	human	iPSC	cardiomyocytes	(Panels	A	&	B).	Both	CBD	(1	μmol	L−1;	Panel	C)	and	Y-	27632	(10	&	
50	μmol	L−1;	Panel	D)	markedly	reduced	the	peak	DMR	response	to	LPI	(10	μmol	L−1).	ATP	(100	μmol	L−1)	was	employed	as	a	positive	control	
in	all	experiments.	Values	are	shown	as	mean	±	SEM;	n	=	4	experiments	performed	using	separate	cell	preparations	for	all	groups.	*P < 0.001 
vs vehicle; #P <	0.001	vs	LPI	alone.	AU	=	Arbitrary	Units
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coronary	circulation	(to	mimic	exposure	to	platelet-	derived	LPI),	has	
a detrimental influence on the outcome of an ischemia/reperfusion 
insult,	suggesting	that	patients	with	elevated	coronary	LPI	levels	at	
the	time	of	an	AMI	may	sustain	greater	damage	to	the	heart.	This	
action	of	LPI	is	most	likely	to	be	at	the	level	of	the	cardiomyocyte,	
since	the	use	of	a	global	no-	flow	ischemia	model	rules	out	an	adverse	
(vasoconstrictor)	effect	of	LPI	on	the	coronary	circulation	during	is-
chemia	and,	in	any	case,	in	vivo	studies	show	that	LPI	causes	a	de-
pressor rather than a constrictor response.1 It is noteworthy that we 
did	not	see	any	difference	in	the	extent	of	injury	between	vehicle-	
treated	WT	and	GPR55−/−	hearts,	supporting	the	notion	that	there	is	
no	endogenous	release	of	LPI	from	the	heart	during	I/R	and	that	the	
source	of	elevated	LPI	seen	during	acute	coronary	events	is	extra-	
cardiac.	Indeed,	in	a	separate	study	(manuscript	in	preparation),	we	
have	found	that	total	LPI	levels	in	WT	hearts	subjected	to	I/R	are	in	
fact significantly lower than in sham hearts. Our studies also show 
that	 administration	of	 LPI	 at	 the	 time	of	 reperfusion	does	not	ex-
acerbate	 the	 extent	 of	 injury,	 demonstrating	 that	 the	 LPI-	induced	
increase in myocardial injury occurs during ischemia.
We have also confirmed that the increase in infarct size fol-
lowing	LPI	application	to	isolated	hearts	is	via	activation	of	GPR55	
receptors,	since	 infarct	size	 in	hearts	from	GPR55−/− mice was not 
increased	by	LPI.	Utilizing	hearts	lacking	GPR55,	as	opposed	to	the	
GPR55	antagonist	CBD,	was	a	more	appropriate	way	of	demonstrat-
ing	a	role	for	the	receptor	since,	although	we	know	that	CBD	acts	
relatively	selectively	at	GPR55	in	cell	systems,	when	used	in	whole	
tissue or in vivo	studies	it	displays	a	more	complex	pharmacology.47 
Moreover,	 CBD	 itself	 reduces	 infarct	 size9,46 through mechanisms 
that	are	not	exclusively	GPR55-	mediated,	and	which	could	have	con-
founded the present studies.
The	amelioration	of	the	infarct-	extending	effect	of	LPI	in	WT	
hearts	 by	 the	ROCK	 inhibitor	Y-	27632	 supports	 the	notion	 that	
cardiomyocyte	ROCK	activation	by	LPI	is,	at	least	in	part,	respon-
sible	 for	 the	 exacerbation	 of	 I/R	 injury.	 ROCK	 expression	 is	 in-
creased in the postinfarct heart29 and there is strong evidence that 
ROCK	activation	is	an	important	contributor	to	the	expansion	of	
I/R	injury,	since	ROCK	inhibition	reduces	I/R	injury	through	multi-
ple mechanisms including a suppression of endoplasmic reticulum 
F IGURE  4 LPI	induces	ROCK2	and	p38	MAPK	activation	in	murine	iPSC	cardiomyocytes.	LPI	(1	&	10	μmol	L−1)	produced	a	concentration-	
dependent	increase	in	ROCK2	phosphorylation	(Panel	A;	*P <	0.05	vs	control)	that	was	completely	inhibited	in	the	presence	of	both	Y-	27632	
(50	μmol	L−1)	and	CBD	(1	μmol	L−1)	(Panel	B;	*P	<	0.05	vs	LPI	response).	LPI	also	induced	p38	MAPK	activation	that	was	sensitive	to	both	
Y-	27632	and	CD	(Panel	C;	*P <	0.05	vs	LPI	response).	In	contrast,	there	was	no	evidence	of	significant	JNK	activation	(Panel	D)	or	caspase-	3	
cleavage	(Panel	E)	in	response	to	challenge	with	LPI.	Data	(mean	±	SEM)	is	expressed	as	the	ratio	of	phosphorylated	to	total	protein	
(corrected	for	protein	content);	n	=	3	experiments	performed	on	separate	cell	preparations.	Western	Blots	are	representative	results
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(ER)	 stress	 and	 apoptotic	 signaling	 pathways	 that	 are	 activated	
during reperfusion.4,29,30	LPI	has	been	shown	(in	HEK	cells)	to	in-
duce	p38	mitogen-	activated	protein	kinase	 (MAPK)	downstream	
of	ROCK,35	and	in	the	cardiomyocyte	activation	of	MAPK	during	
prolonged	ischemia	induces	a	pro-	apoptotic	response.26	Here	we	
have	 shown	 that	 LPI	 similarly	 induces	 p38	 MAPK	 activation	 in	
cultured	miPSC	cardiomyocytes	downstream	of	ROCK	activation,	
although this is not associated with induction of apoptotic signal-
ing	 pathways	 (JNK	 and	 caspase-	3).	However,	 p38	MAPK	 inhibi-
tion during I/R has been shown to prevent mitochondrial reactive 
oxygen	 species	 production	 and	 Ca2+	 overload,42 pointing to a 
F IGURE  5 LPI-	induced	ROCK2	phosphorylation	is	a	sustained	response.	Both	short	(10	minutes;	Panel	A)	and	prolonged	(40	minutes;	
Panel	B)	exposure	to	LPI	demonstrated	sustained	ROCK2	phosphorylation	in	murine	iPSC	cardiomyocytes.	A	second	GPR55	antagonist	
CID16020046	(10	μmol	L−1)	prevented	the	response	at	both	timepoints,	providing	further	supporting	evidence	that	the	effect	of	LPI	is	
mediated	through	GPR55.	Data	(mean	±	SEM)	are	expressed	as	the	ratio	of	phosphorylated	to	total	ROCK	(corrected	for	protein	content);	
n	=	3	experiments	performed	on	separate	cell	preparations.	Western	Blots	are	representative	results.	*P <	0.05	vs	LPI	response
F IGURE  6 LPI	increases	myocardial	infarct	size	in	hearts	from	wild	type,	but	not	GPR55−/−,	mouse	hearts.	Panels	A-	F	show	
representative	images	of	TTC	(1%)	staining	of	transverse	slices	of	hearts,	delineating	viable	(red)	and	infarcted	(white)	tissue,	from	WT	mice	
exposed	to	vehicle	(A),	LPI	(10	μmol	L−1;	B)	and	LPI	plus	10	μmol	L−1	(C)	or	50	μmol	L−1	(D)	Y-	27632	prior	to	30	minutes	global	ischemia	and	
30	minutes	reperfusion.	Images	of	hearts	from	GPR55−/−	mice	challenged	with	vehicle	(E)	or	LPI	(F)	are	also	shown.	Panel	G	shows	that	LPI	
(10	μmol	L−1)	applied	10	minutes	before	the	onset	of	global	ischemia	increased	infarct	size	in	hearts	from	WT	(n	=	14	each	for	vehicle	and	
LPI),	but	not	GPR55−/−	(n	=	5	for	vehicle	and	n	=	7	for	LPI)	mice,	but	not	when	applied	5	minutes	into	reperfusion	(WT	hearts	only;	n	=	9).	
*P <	0.05	vs	vehicle.	The	higher	concentration	(50	μmol	L−1)	of	the	ROCK	inhibitor	Y-	27632	reversed	the	effects	of	LPI-	induced	injury	in	WT	
hearts	(Panel	H;	n	=	5	per	group;	*P	<	0.05	vs	vehicle;	#P <	0.05	vs	LPI	alone)
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possible	mechanism	underlying	 the	 LPI-	induced	exacerbation	of	
injury.
LPI	 also	promotes	Ca2+	 entry	 (via	LTCCs52)	 into	cardiomyocytes,	
which in the setting of I/R would induce cellular injury through the in-
duction of cardiomyocyte Ca2+	overload,	activation	of	mitochondrial	
KATP	channels	and	subsequent	opening	of	the	mitochondrial	permea-
bility	transition	pore	(mPTP13).	Although	an	association	between	LPI-	
induced Ca2+	entry	via	LTCC's	and	activation	of	ROCK	has	not	been	
investigated	in	cardiomyocytes,	Ca2+	entry	via	LTCC's	has	been	linked	
to	ROCK	activation	 in	 vascular	 smooth	muscle	 cells.31	Moreover,	 in	
GPR55-	expressing	HEK	cells	LPI	activates	phospholipase	C	(PLC)	via	
a	ROCK-	dependent	pathway,19	with	the	subsequent	production	of	IP3 
and stimulated Ca2+	 release	 from	 the	 sarcoplasmic	 reticulum,	which	
again would cause Ca2+	overload.	ROCK	has	also	been	shown	to	work	
in	 concert	with	 low	 voltage-	activated	 T-	type	Ca2+	 channels	 (Cav3.2	
channel),	 which	 have	 also	 been	 implicated	 in	 Ca2+ overload during 
myocardial ischemia.34	Clearly	these	are	potential	mechanisms	of	LPI-	
induced	cardiomyocyte	injury	that	require	further	investigation.
Although	an	investigation	of	the	effect	of	ROCK	inhibition	per se 
on	infarct	size	was	not	a	primary	aim	of	the	present	study,	it	is	inter-
esting	that,	in	contrast	to	other	studies	showing	an	infarct-	sparing	
effect	 of	ROCK	 inhibition,	we	did	 not	 see	 an	 infarct-	reducing	 ef-
fect	 of	 Y-	27632	 but	 rather	we	 observed	 a	 slight	 (not	 statistically	
significant)	trend	toward	an	increase	in	infarct	size.	There	are	sev-
eral	plausible	explanations	for	this.	First,	ROCK	inhibition	has	been	
shown to decrease infarct size and preserve postinfarction cardiac 
systolic function through various mechanisms including increased 
collateral	blood	flow	to	the	myocardium,51 improved metabolic sta-
tus	of	the	ischemic	tissue,16	reduced	myocardial	fibrosis,29 reduced 
apoptosis and inflammation4 and preservation of the reperfusion 
injury	 salvage	 kinase	 (RISK)	 pathway.30	 Importantly,	 all	 of	 these	
studies used in vivo	models	and	determined	end	points	(inflamma-
tion	and	apoptosis)	that	occur	over	extended	periods	of	time	(hours	
to	days)	after	 reperfusion	or	 implemented	ROCK	 inhibition	at	 the	
time of reperfusion.14	 In	 contrast,	 our	 studies	were	performed	 in	
blood-	free	perfused	hearts	 in	vitro, the hearts were administered 
Y-	27632	prior	to	ischemia	and	relatively	short	(30	minutes)	periods	
of	I/R	(when	the	main	mechanisms	contributing	to	cell	death	are	cal-
cium	overload	and	oxidative	stress)	were	used.	Consistent	with	our	
findings,	ROCK	activation	has	been	shown	to	promote	cardiomyo-
cyte	 survival	 via	 a	 PKD	pathway50 and more recent studies have 
shown	that	the	two	ROCK	isoforms	(ROCK-	1	and	ROCK-	2)	play	op-
posing	roles	 in	 the	heart,	with	ROCK-	1	protecting	against	cardiac	
dysfunction	 and	oxidative	 stress	 and	ROCK-	2	 promoting	 these.43 
Since	Y-	27632	is	a	nonselective	inhibitor	that	has	similar	affinities	
for	both	ROCK	isoforms,2	this	could	explain	why	in	vehicle-	treated	
hearts,	 where	 I/R-	induced	 ROCK-	1	 activation	 predominates	 and	
serves	a	pro-	survival	role,	Y-	27632	had	a	slightly	deleterious	effect,	
while	in	LPI-	stimulated	hearts	where	ROCK-	2	is	activated	(as	shown	
from	our	cardiomyocytes	studies),	 it	prevented	the	ROCK-	2	medi-
ated	extension	of	injury.
Off-	target	 actions	 of	Y-	27632	 for	ROCK	 could	 also	 potentially	
account	for	our	findings	since,	when	screened	against	a	panel	of	ki-
nases	it	has	been	shown	to	inhibit	protein	kinase-	2	(PRK28;	PKC	ep-
silon	(PKCε)	and	protein	kinase	N1	(PKN).2	The	expression	of	PRK2	
is	very	low	in	the	heart,38	making	it	an	unlikely	target,	but	PKN	is	a	
pro-	survival	kinase	expressed	in	response	to	I/R	injury44	while	PKCε 
is a known trigger of delayed preconditioning.20,48 Since our model 
F IGURE  7 Proposed	signaling	pathway	for	LPI	in	cardiomyocytes	that	contributes	to	exacerbation	of	I/R	injury.	LPI	is	known	to	increase	
intracellular	calcium	in	cardiomyocytes	via	direct	entry	through	LTCC's	and	through	PLC/IP3-	mediated	release	from	the	sarcoplasmic	
reticulum	(black	arrows).	Here	we	have	shown	that	LPI	results	in	both	ROCK	and	p38	MAPK	activation	(blue	arrows);	while	p38	MAPK	
activation	has	been	linked	to	a	pro-	apoptotic	effect	during	ischemia	(pink),	lack	of	evidence	of	activation	of	pro-	apoptotic	pathways	suggests	
this	is	not	the	cause	of	LPI-	induced	cardiomyocyte	cell	injury.	The	proposed	pathways	(red	arrows)	are	p38	MAPK-	induced	mitochondrial	
release of Ca2+ and ROS production
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did	not	employ	a	preconditioning	protocol,	inhibition	of	PKN	would	
be	 the	most	 likely	 alternative	mechanism	 of	 the	 infarct-	extending	
effect	of	Y-	27632.
In	 summary,	 we	 present	 the	 novel	 finding	 that	 LPI	 activates	
murine	and	human-	induced	pluripotent	stem	cell	cardiomyocytes	
via	 a	 GPR55/RhoA/ROCK/p38	 MAPK-	dependent	 pathway,	 and	
that	this	same	pathway	is	responsible	for	the	exacerbation	of	 in-
jury	seen	in	hearts	challenged	with	LPI	prior	to	an	ischemia/reper-
fusion insult. While the precise signaling pathways that ultimately 
result	in	a	greater	injury	response	following	LPI	challenge	remain	
to	be	elucidated,	based	upon	the	knowledge	of	signaling	pathways	
in	 other	 cell	 types	 we	 hypothesize	 (Figure	 7)	 that	 LPI	 activates	
ROCK	both	directly	and	indirectly	(via	Ca2+	entry),	which	(i)	further	
increases [Ca2+]i	 through	 IP3-	mediated	 release	 from	 intracellular	
stores	and	 (ii)	 activates	p38	MAPK	to	 induce	mitochondrial	ROS	
production and Ca2+	overload,	which	together	result	in	enhanced	
tissue injury.
Of	significant	clinical	application	is	our	demonstration	that	LPI,	
at	 clinically	 relevant	 concentrations,	 induces	 activation	 in	 human-	
induced pluripotent stemcell cardiomyocytes through precisely the 
same mechanism as that seen in murine cells. When taken alongside 
reports	that	LPI	levels	are	increased	in	the	coronary	circulation	in	pa-
tients	with	ACS,	our	data	implicate	LPI	as	a	contributor	to	the	extent	
of myocardial injury in the clinical setting.
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